期刊文献+

良性前列腺增生症的药物治疗与评价 被引量:4

Evaluation on Drug Treatment for Benign Prostatic Hyperplasia
下载PDF
导出
摘要 目的:伴随老龄社会深化和人数增加,属于老年医学范畴的一组泌尿系统疾病(良性前列腺增生症、前列腺癌、前列腺炎、勃起功能障碍、早泄和膀胱过度活动症)的治疗正日益受到关注,用药情况呈明显上升趋势,本文对抗前列腺增生药的临床应用进行分析评价。方法:采用国内外文献分析方法。结果与结论:抗良性前列腺增生症药的合理和安全应用尤为重要。 OBJECTIVE:With the deepening of ageing society and increase of aging population,the treatment for a group of urinary system diseases belonging to gereology including benign prostatic hyperplasia,prostatic cancer,prostatitis,erectile dysfunction,prospermia and overactive bladder has attracted considerable attention.The use of the drugs for these diseases showed a sharp increase.In this paper,we evaluated the clinical use of the drugs against prostatic hyperplasia.METHODS:The pertinent literature both at home and abroad was analyzed.RESULTS CONCLUSION:It is especially important to achieve rational use of drugs against benign prostatic hyperplasia.
作者 范治国 刘航
出处 《中国医院用药评价与分析》 2012年第11期964-966,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 良性前列腺增生症 5Α还原酶抑制剂 Α受体阻断剂 合理用药 Benign prostatic hyperplasia 5 alpha-reductase inhibitor(5ARI) α-receptor blocker Rational drug use
  • 相关文献

参考文献12

  • 1Song K,Choo MS,Lee KS. The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia:evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility[J].Urology,2011,(05):1177-1182. 被引量:1
  • 2潘沛,吕加国.α_(1A)-受体拮抗剂研究新进展[J].中国药学杂志,2006,41(20):1521-1524. 被引量:14
  • 3Nickel JC,Gilling P,Tammela TL. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia:the Enlarged Prostate International Comparator Study(EPICS)[J].British Journal of Urology International,2011,(03):388-394. 被引量:1
  • 4Roehrborn CG,Siami P,Barkin J. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia:4-year results from the CombAT study[J].European Urology,2010,(01):123-131. 被引量:1
  • 5徐骏,钱伟庆,宋建达.比较不同剂量舍尼通在防止良性前列腺增生疾病进程中的作用[J].中华男科学杂志,2008,14(6):533-537. 被引量:15
  • 6王化明,张军民,任戈.植物制剂舍尼通治疗前列腺增生[J].临床医学,2010,30(6):24-25. 被引量:3
  • 7张祥华.良性前列腺增生症的药物治疗[J].中国医院用药评价与分析,2011,11(7):579-581. 被引量:8
  • 8Kaplan SA,Holtgrewe HL,Bruskewitz R. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia[J].Urology,2001,(06):1073-1077. 被引量:1
  • 9Clark RV,Hermann DJ,Cunningham GR. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride,a dual 5alpha-reductase inhibitor[J].Journal of Clinical Endocrinology and Metabolism,2004,(05):2179-2184. 被引量:1
  • 10Elterman DS,Lawrentschuk N,Guns E. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors[J].The Journal of Urology,2010,(05):2085-2089. 被引量:1

二级参考文献31

共引文献32

同被引文献49

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部